Group 1 - Voyager Therapeutics, Inc. is a biotechnology company focused on using genetics to treat neurological diseases, with a pipeline that includes programs for Alzheimer's disease, Friedreich's ataxia, Parkinson's disease, and ALS [2] - The company will participate in several upcoming investor conferences, including the Citi and Baird fireside chats, where it plans to present preclinical data on its non-viral delivery platform [1][4] - Voyager's TRACER™ AAV capsid discovery platform is utilized to create novel capsids for high brain penetration of genetic medicines [2] Group 2 - The company has partnerships with major pharmaceutical firms such as Alexion, AstraZeneca Rare Disease, Novartis Pharma AG, and Neurocrine Biosciences, Inc. [2] - Upcoming conference details include the Citi's 2025 Biopharma Back to School Conference on September 2, 2025, and the Wells Fargo Healthcare Conference on September 3, 2025 [4] - The company aims to highlight its innovative approaches to neurotherapeutics during these conferences, particularly its methods for crossing the blood-brain barrier [4]